Quantum Biopharma (QNTM) to Release Quarterly Earnings on Friday

Quantum Biopharma (NASDAQ:QNTM) is expected to announce its results before the market opens on Friday, March 27th. Analysts expect the company to announce earnings of ($0.22) per share for the quarter.

Quantum Biopharma Price Performance

NASDAQ QNTM opened at $4.73 on Wednesday. The firm’s fifty day moving average price is $4.13 and its 200 day moving average price is $8.98. Quantum Biopharma has a 12 month low of $2.07 and a 12 month high of $38.25. The company has a market capitalization of $18.07 million, a price-to-earnings ratio of -0.43 and a beta of 0.32.

Analyst Ratings Changes

Several brokerages have issued reports on QNTM. Wall Street Zen lowered Quantum Biopharma from a “hold” rating to a “sell” rating in a report on Saturday, January 24th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Quantum Biopharma in a research note on Monday, December 29th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock has a consensus rating of “Sell”.

Institutional Trading of Quantum Biopharma

An institutional investor recently bought a new position in Quantum Biopharma stock. Jane Street Group LLC acquired a new stake in Quantum Biopharma Ltd. (NASDAQ:QNTM) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 10,892 shares of the company’s stock, valued at approximately $80,000. Jane Street Group LLC owned approximately 0.29% of Quantum Biopharma at the end of the most recent quarter. Institutional investors own 1.24% of the company’s stock.

Quantum Biopharma Company Profile

Quantum Biopharma Ltd. is a biotechnology pharmaceutical research and development company, which focuses on the cultivation, process, and sale of medical cannabis. It operates through the Biotechnology and Strategic Investments segments. The Biotechnology segment is involved in the research and development of the company’s three drug candidates consisting of FSD-PEA, Lucid-PSYCH, and Lucid-MS. The Strategic Investments segment is focused on generating returns and cashflow through the issuance of loans secured by residential or commercial property.